Finance and Investment in the BioPharma Market

Finance / Investment		email this page print page
Title		Publication Date		Price
Forecasting for the Pharmaceutical Industry		October 2006		£75
Financial Markets Research: Palatin Technologies' Bremelanotide Competition and regulatory risk cloud potential		September 2006		£2195
Financial Markets Research: Sirona Dental Systems Likely struggle for impressive annual growth despite strong reputation and technology		September 2006		£2195
Financial Markets Research: Spectrum Pharmaceuticals' Oral Satraplatin Oral therapy to take share in second-line hormone-refractory prostate cancer market		September 2006		£2195
Pharmaceutical CME Measuring Program Effectiveness in the Compliance Environment		September 2006		£2220
Financial Markets Research: Indevus Pharmaceuticals' Sanctura XR Last-to-market entrant unlikely to make an impact in crowded OAB market		August 2006		£2195
Financial Markets Research: Santarus, Inc.'s Zegerid Fast-acting formulation gaining momentum in GERD		August 2006		£2195
Financial Markets Research: Endo Pharmaceuticals’ Lidoderm Physician survey indicates increased use likely to fuel above-consensus sales growth		August 2006		£2195
Financial Markets Research: Renovis, Inc.'s NXY-059 Safety profile and unmet need could drive approval		August 2006		£2195
Financial Markets Research: ASCO Review Part IICO 2006 Annual Meeting A summary of highlights presented at the ASCO 2006 Annual Meeting		August 2006		£2195
Financial Markets Research: Bausch & Lomb's Contact Lens Solution Withdrawal ReNu MultiPlus likely to struggle in attempt to regain market share		August 2006		£2195
Financial Markets Research: ASCO Review Part II A summary of highlights presented at the ASCO 2006 Annual Meeting		August 2006		£2195
Alternative Financial Solutions for Medical Technology Acquisition		May 2005		£2495
Venture Capital Analyst: Health Care Edition		January 2005		£705
VentureWire Lifescience Daily newsletter		January 2005		£275
Venture Capital Analyst Health Care Sourcebook, The		April 2004		£260